Dyne Therapeutics, Inc. $DYN Shares Bought by Moore Capital Management LP

Moore Capital Management LP raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 288.2% during the 2nd quarter, Holdings Channel reports. The firm owned 305,794 shares of the company’s stock after purchasing an additional 227,029 shares during the quarter. Moore Capital Management LP’s holdings in Dyne Therapeutics were worth $6,792,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of DYN. Hilton Head Capital Partners LLC purchased a new stake in Dyne Therapeutics in the 1st quarter worth approximately $26,000. Strs Ohio acquired a new position in shares of Dyne Therapeutics in the 4th quarter valued at about $51,000. Allworth Financial LP purchased a new stake in Dyne Therapeutics during the second quarter worth approximately $62,000. Aster Capital Management DIFC Ltd purchased a new stake in Dyne Therapeutics during the 4th quarter worth $84,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares in the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DYN. Sanford C. Bernstein increased their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Cantor Fitzgerald assumed coverage on shares of Dyne Therapeutics in a research report on Thursday, July 23rd. They issued an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Evercore set a $33.00 target price on shares of Dyne Therapeutics in a report on Friday, May 15th. Finally, Royal Bank Of Canada upped their price objective on Dyne Therapeutics from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.42.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $25.07 on Monday. The company has a market capitalization of $4.68 billion, a price-to-earnings ratio of -7.53 and a beta of 1.07. Dyne Therapeutics, Inc. has a twelve month low of $11.92 and a twelve month high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The firm has a 50-day moving average of $24.37 and a two-hundred day moving average of $20.08.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, analysts expect that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Erick Lucera sold 2,362 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total transaction of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company’s stock, valued at $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,139,196 shares of company stock worth $99,449,852 in the last 90 days. 9.46% of the stock is owned by company insiders.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.